Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Thyroid Neoplasms: full-pipeline trial registry

4 of 8 indexed Thyroid Neoplasms trials are currently recruiting.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Thyroid Neoplasms: 8 US clinical trials tracked, 4 recruiting.

Thyroid Neoplasms is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Bayer, running 2 of these trials.

Enrollment posture brief

Registry condition thyroid-neoplasms

OPEN 4 | RECR 50% | LATE 1 | EARLY 1 | RANK #2176 | SPON 2

Volume-matched condition peers

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%Thyroid Neoplasms (this)50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near Thyroid Neoplasms

Thyroid Neoplasms lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Thyroid Neoplasms on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Thyroid Neoplasms is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Thyroid Neoplasms research.

    Bayer accounts for 2 of 8 trials (25%). 7 distinct sponsors appear on at least one study for this condition label.

  3. Typical Thyroid Neoplasms enrolment sits around 417 participants.

    Median target enrolment is 417 among the 8 trials that report a genuine target (sentinel values excluded). 3 of those (37.5%) plan for fewer than 100 participants.

  4. Thyroid Neoplasms splits between interventional and observational designs.

    4 interventional and 4 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 31

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Top Sponsors

Bayer 2 trials
Hadassah Medical Organization 1 trials
Georgetown University 1 trials
Dartmouth-Hitchcock Medical Center 1 trials
Eli Lilly and Company 1 trials
The University of Texas Health Science Center at San Antonio 1 trials
National Cancer Institute (NCI) 1 trials

Named interventions

Most-linked intervention names on Thyroid Neoplasms records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Sorafenib (Nexavar, BAY43-9006) Drug
2 trials
Other Multikinase inhibitors Drug
1 trials
Electrical Impedance Scanning (EIS) of the Thyroid gland Device
1 trials
LOXO-260 Drug
1 trials
Genetic screening Genetic
1 trials
Active Monitoring Procedure
1 trials
Treatment as Usual (TAU) Other
1 trials
Radioactive Iodine Support (RAI Support) Behavioral
1 trials

US sites by state

Facility locations filed on Thyroid Neoplasms trials. A trial with sites in several states counts in each.

Texas 4 trials
Pennsylvania 3 trials
New York 3 trials
Michigan 3 trials
Massachusetts 3 trials
Georgia 3 trials
District of Columbia 3 trials
California 3 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Thyroid Neoplasms page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Thyroid Neoplasms trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Bayer sponsors the most Thyroid Neoplasms trials on record, review their full trial history before evaluating a specific study. See Bayer's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Thyroid Neoplasms condition card totals 8 registered trials; most-linked intervention Sorafenib (Nexavar, BAY43-9006); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.